GMAB Stock Recent News

Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Jonathan Chang - LeeRink Partners Paul Jeng - Guggenheim Securities, LLC Zain Ebrahim - JPMorgan Chase Suzanne van Voorthuizen - Kempen & Co. Xian Deng - UBS Yaron Werber - TD Securities Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Matthew Phipps - William Blair Alistair Campbell - RBC Capital Markets Vikram Purohit - Morgan Stanley Etzer Darout - BMO Capital Markets Operator Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy Genmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab Genmab revenue increased 29% compared to the first nine months of 2023, to DKK 15,085 million Genmab 2024 financial guidance updated “The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The additional approval for TEPKINLY, along with positive data presentations for our promising late-stage assets acasunlimab and rinatabart sesutecan (Rina-S), underscore the

Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab's pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition.

Media Release COPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief Executive Officer , Jan van de Winkel, Ph.D. and C hief F inancial O fficer , Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 1 9 , 202 4 at 4:30 PM CET / 10 : 30 AM EST.

Media Release COPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patients New and updated data from EPCORE ® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (Nasdaq: GMAB ) announced today more than 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's lymphoma (NHL) subtypes, will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the San Diego Convention Center in San Diego, California, and online, December 7-10. The breadth of the epcoritamab development program will be featured at this year's ASH in four oral presentations.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patients New and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (Nasdaq: GMAB) announced today more than 20 abstracts evaluating epc.

Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world.